These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 13542306)

  • 41. [Sectional blood oxymetry in rheumatic disease].
    SCALABRINO R; PASQUARIELLO G
    Minerva Med; 1955 Feb; 46(14):445-6. PubMed ID: 14355908
    [No Abstract]   [Full Text] [Related]  

  • 42. [Serum uric acid increase in skin disease patients, especially in psoriasis patients].
    KORTING GW; KAFFARNIK H
    Dermatol Wochenschr; 1958 Dec; 138(50):1359-62. PubMed ID: 13630086
    [No Abstract]   [Full Text] [Related]  

  • 43. [Behavior of the blood copper curve after intravenous loading with copper gluconate in rheumatic diseases].
    CAIOZZO A; SAVAGNONE E
    Boll Soc Ital Biol Sper; 1953 Apr; 29(4):672-5. PubMed ID: 13105999
    [No Abstract]   [Full Text] [Related]  

  • 44. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey.
    Choi HK; Liu S; Curhan G
    Arthritis Rheum; 2005 Jan; 52(1):283-9. PubMed ID: 15641075
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey.
    Choi HK; Curhan G
    Arthritis Rheum; 2007 Jun; 57(5):816-21. PubMed ID: 17530681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study.
    Shankar A; Klein R; Klein BE; Nieto FJ
    J Hum Hypertens; 2006 Dec; 20(12):937-45. PubMed ID: 17024135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
    Pellicano R; Puglisi G; Ciancio A; Balzola F; Saracco G; Ciccone G; Baldi I; Abate ML; Smedile A; Rizzetto M
    J Med Virol; 2008 Apr; 80(4):628-31. PubMed ID: 18297716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid.
    Lin JD; Chiou WK; Chang HY; Liu FH; Weng HF
    Metabolism; 2007 Jun; 56(6):751-6. PubMed ID: 17512306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparative examinations of the level of plasma tryptophan & of other clinical tests in the course of treatment of lingering rheumatic diseases].
    SOKOLOWSKI A; GABRYELSKI W
    Postep Reumatol; 1957; 3():49-56. PubMed ID: 13542305
    [No Abstract]   [Full Text] [Related]  

  • 50. [C-reactive protein in rheumatic diseases].
    OKA M; KYTILA J
    Duodecim; 1957; 73(7-8):396-407. PubMed ID: 13473708
    [No Abstract]   [Full Text] [Related]  

  • 51. [Effect of phenylbutazone on uric acid in plasma and erythrocytes; relation to clinical phenomena].
    LEVY M; SICHERE RM
    Rev Rhum Mal Osteoartic; 1955 Mar; 22(3):225-33. PubMed ID: 14396123
    [No Abstract]   [Full Text] [Related]  

  • 52. [Experience with C-reactive protein in rheumatic disease].
    NOGUERA H; HURTADO R; DUSSAILLANT G
    Rev Med Chil; 1958 Feb; 86(2):119-25. PubMed ID: 13542992
    [No Abstract]   [Full Text] [Related]  

  • 53. [Level of uric acid in champion athletes].
    Horváth G
    Acta Chir Orthop Traumatol Cech; 1968 Feb; 35(1):89-91. PubMed ID: 5669453
    [No Abstract]   [Full Text] [Related]  

  • 54. Phenylbutazone metabolites: antirheumatic, sodium-retaining and uricosuric effects in man.
    YU TF; BURNS JJ; PATON BC; GUTMAN AB; BRODIE BB
    J Pharmacol Exp Ther; 1958 May; 123(1):63-9. PubMed ID: 13539792
    [No Abstract]   [Full Text] [Related]  

  • 55. [Data furnished by paper electrophoresis in rheumatic diseases].
    LAYANI F; ASCHKENASY A; BENGUI A
    Rev Rhum Mal Osteoartic; 1957 Nov; 24(11):711-39. PubMed ID: 13528479
    [No Abstract]   [Full Text] [Related]  

  • 56. [Determination of C-reactive protein in rheumatic diseases].
    ARMAS-CRUZ R; ARMIJO G; DEL RIO R; GONZALEZ F; VICUNA JP; LOBOPARGA G
    Rev Med Chil; 1957 Jun; 85(6):329-33. PubMed ID: 13494920
    [No Abstract]   [Full Text] [Related]  

  • 57. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.
    Niskanen LK; Laaksonen DE; Nyyssönen K; Alfthan G; Lakka HM; Lakka TA; Salonen JT
    Arch Intern Med; 2004 Jul; 164(14):1546-51. PubMed ID: 15277287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Blood coagulation as an indicator of the activity of the rheumatic process].
    Gritsiuk AI
    Sov Med; 1965 Aug; 28(8):9-15. PubMed ID: 5296683
    [No Abstract]   [Full Text] [Related]  

  • 60. [The blood cholesterol and cholesterolytic power of the serum in rheumatic diseases].
    ISEMEIN L; LALLEMAND A
    Rev Rhum Mal Osteoartic; 1953 Oct; 20(10):685-91. PubMed ID: 13135210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.